PTSD Drug Breakthrough: Treating Trauma Effectively
Breakthrough Finding Identifies Astrocytic GABA as Key Driver of PTSD, Paving Way for Novel Treatments
Seoul, South Korea – In a landmark study that could revolutionize the treatment of Post-Traumatic Stress Disorder (PTSD), researchers have pinpointed a critical cellular mechanism driving the inability to extinguish fear memories, a hallmark of the debilitating condition. the groundbreaking work, led by Dr. C. Justin LEE at the IBS Center for Cognition and Sociality and Professor LYOO In Kyoon at Ewha Womans University, reveals that excessive gamma-aminobutyric acid (GABA) produced by astrocytes, the brain’s support cells, actively impairs the extinction of traumatic memories. This discovery not only sheds new light on the neurobiology of PTSD but also offers a promising therapeutic avenue with a drug already showing efficacy in preclinical trials.
PTSD, characterized by persistent intrusive memories, avoidance of trauma-related stimuli, and hyperarousal, remains a meaningful challenge for current treatment strategies. Existing medications primarily targeting serotonin pathways offer limited relief for many individuals. This new research, however, shifts the focus to the medial prefrontal cortex (mPFC), a brain region crucial for fear regulation. Through extensive brain imaging studies involving over 380 participants, the team observed unusually high GABA levels and reduced cerebral blood flow in the mPFC of individuals with PTSD. Crucially, a decrease in GABA levels correlated with clinical improvement, underscoring the chemical’s central role in recovery.
The examination delved deeper to uncover the source of this aberrant GABA production. By examining postmortem human brain tissue and utilizing PTSD-like mouse models, the researchers made a pivotal discovery: it is not neurons, but astrocytes, the star-shaped glial cells, that are responsible for the abnormal GABA surge. This excessive GABA is generated via the enzyme monoamine oxidase B (MAOB). The resulting imbalance disrupts neural activity, effectively blocking the brain’s natural ability to extinguish fear memories, even long after the threat has subsided.
This critical insight led the researchers to a potential therapeutic solution. They identified KDS2010,a brain-permeable drug developed at IBS that selectively inhibits MAOB. when administered to mice exhibiting PTSD-like symptoms, KDS2010 demonstrated remarkable efficacy. The drug normalized brain activity, reduced GABA levels, restored blood flow in the mPFC, and crucially, re-enabled the memory extinction mechanisms. This preclinical success strongly suggests that targeting astrocytic MAOB is a viable therapeutic strategy for PTSD.
A significant hurdle in psychiatric research is bridging the gap between human clinical observations and the underlying cellular mechanisms. The research team employed a sophisticated “reverse translational” approach, starting with human brain imaging data and working backward to identify the cellular source of dysfunction. This strategy allowed them to confirm the mechanism in animal models and test the efficacy of KDS2010. This innovative methodology has not only illuminated the role of astrocytes in psychiatric disorders but also highlighted their active, rather than passive, contribution to symptom growth.
“This study is the first to identify astrocyte-derived GABA as a key pathological driver of fear extinction deficit in PTSD,” stated Dr. WON Woojin, a postdoctoral researcher and co-first author of the study. “Our findings not only uncover a novel astrocyte-based mechanism underlying PTSD, but also provide preclinical evidence for a new therapeutic approach using an MAOB inhibitor.”
Director C.Justin LEE further emphasized the significance of the findings: “This work represents a accomplished example of reverse translational research, where clinical findings in humans guided the discovery of underlying mechanisms in animal models. By identifying astrocytic GABA as a pathological driver in PTSD and targeting it via MAOB inhibition, the study opens a completely new therapeutic paradigm not only for PTSD but also for othre neuropsychiatric disorders such as panic disorder, depression, and schizophrenia.”
With KDS2010 currently progressing through Phase 2 clinical trials in humans, this discovery holds immense promise for individuals whose symptoms have been resistant to conventional treatments. The research team plans to further explore astrocyte-targeted therapies for a range of neuropsychiatric conditions, perhaps ushering in a new era of more effective and targeted treatments.